Locke Lord Chicago Team Secures Decision in Favor of Broad Institute From U.S. Patent and Trademark Office in CRISPR Patent Interference

A Locke Lord team that included Steven Trybus, Wasim Bleibel, Leah Brackensick and Hugh Balsam (all of Chicago) together with co-counsel represented The Broad Institute, Inc., Massachusetts Institute of Technology and President and Fellows of Harvard College (collectively, Broad) in the second patent interference proceeding involving claims to CRISPR-CAS9 systems for use in eukaryotic cells. On February 28, 2022, the Patent Trial and Appeal Board issued its judgment and decision in that interference confirming that Broad’s patents, including those for genome editing, were properly issued, are patentably distinct and not reasonably expected from results of biochemical “test tube” experiments. For more information, see the Broad Institute website.
Posted on March 1, 2022